

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 200043117 B2
(10) Patent No. 774191

- (54) Title
Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects
- (51)⁷ International Patent Classification(s)
A61K 031/205 A61P 009/10
A61K 035/72
- (21) Application No: **200043117** (22) Application Date: **2000.04.07**
- (87) WIPO No: **WO00/62773**
- (30) Priority Data
- | | | |
|--------------------|-------------------|--------------|
| (31) Number | (32) Date | (33) Country |
| RM99A000230 | 1999.04.16 | IT |
- (43) Publication Date : **2000.11.02**
(43) Publication Journal Date : **2001.01.04**
(44) Accepted Journal Date : **2004.06.17**
- (71) Applicant(s)
Sigma-Tau Healthscience S.p.A.
- (72) Inventor(s)
Claudio Cavazza
- (74) Agent/Attorney
Davies Collison Cave, Level 15, 1 Nicholson Street, MELBOURNE VIC 3000
- (56) Related Art
US 5998474

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



43117/00

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K 31/205, 35/72, A61P 9/10</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/62773 (43) International Publication Date: 26 October 2000 (26.10.00)</p>
<p>(21) International Application Number: PCT/IT00/00129 (22) International Filing Date: 7 April 2000 (07.04.00) (30) Priority Data: RM99A000230 16 April 1999 (16.04.99) IT (71) Applicant (for all designated States except US): SIGMA-TAU HEALTHSCIENCE S.P.A. [IT/IT]; Via Treviso, 4, I-00040 Pomezia (IT). (72) Inventor; and (75) Inventor/Applicant (for US only): CAVAZZA, Claudio [IT/IT]; Piazza Campitelli, 2, I-00186 Roma (IT). (74) Agents: CAVATTONI, Fabio et al.; Cavattoni - Raimondi, Viale dei Parioli, 160, I-00197 Roma (IT).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: COMPOSITION COMPRISING A CARNITINE AND GLUTATHIONE, USEFUL TO INCREASE THE ABSORPTION OF GLUTATHIONE AND SYNERGIZE ITS EFFECTS</p>		
<p>(57) Abstract</p> <p>A composition is disclosed useful to increase the absorption of glutathione and synergize its effects, that, depending on user's conditions, may take the form of a dietary supplement, dietetic support or of an actual medicine, which comprises as characterizing active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof; (b) glutathione or a glutathione-containing yeast; (c) a glutathione-free yeast if the component (b) consists of glutathione.</p>		

Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects

The present invention relates to a composition for the prevention and/or treatment of alterations of those organs which perform the most intense metabolic function, such as the liver, kidneys, cardiovascular system and brain.

More particularly, such composition is useful to treat or prevent hepatitis, nephropathies and cardiovascular or cerebral damages provoked by toxic substances.

10

Accordingly, the composition may take the form and exert the action of a dietary supplement or of an actual medicine, depending upon the support or preventive action, or the strictly therapeutic action, which the composition is intended to exert in relation to the particular individuals it is to be used in.

15

More particularly the present invention relates to an orally, parenterally, rectally, or transdermally administrable composition which comprises in combination:

(a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, optionally in combination with another "carnitine", where for "carnitine" is intended L-carnitine or an

20

alkanoyl L-carnitine selected from the group comprising acetyl L-carnitine, valeryl L-carnitine and isovaleryl L-carnitine or their pharmacologically acceptable salts; and

(b) glutathione or glutathione-containing yeast;

(c) a glutathione-free yeast if the component (b) consists of glutathione.

25

Glutathione (GSH), N-(N-L-L- γ -glutamyl-cysteinyl) glycine, plays an essential role in the organic redox and detoxification reactions. Glutathione is synthesised in the body starting from glutamic acid and cysteine which, in the presence of ATP, form γ -glutamyl-cysteine,

which, again in the presence of ATP, reacts with glycine giving rise to the formation of glutathione. Glutathione is ubiquitously present in the body. Its greatest concentrations, however, are to be found in the liver, heart and brain, i.e. in those organs where the metabolic, energy and detoxification reactions are more important. These tissues also contain glutathione peroxidase and glutathione reductase, which regulate the redox system related to the glutathione cycle, ensuring maintenance of sufficient amounts of reduced glutathione after the latter has been oxidised.

Though the biochemical and detoxifying activities of glutathione have long been known, particularly against heavy metals (which are among the most important environmental pollutants) or against liver-damaging drugs such as paracetamol, only the most recent researches have revealed the predominant role of glutathione among the various redox systems, as well as its specific pharmacological role. A direct involvement of glutathione in exerting a protective effect against the formation of atheromatous plaques has been observed by directly measuring the presence of the glutathione-related antioxidant/pro-oxidant system in such plaques. These researches revealed low concentrations of glutathione and fairly poor activity of the glutathione-related redox system. There was a particularly marked reduction in the glutathione peroxidase concentration and at the same time an increase in the concentration of oxidising factors. These abnormalities are not evident, however, in normal vascular tissue.

Glutathione also plays a major protective role in diseases of the liver. Moreover, the liver-protecting effects of many drugs are mediated by glutathione. It has also been reported that increased glutathione may reduce liver transplant rejection.

At the neurocerebral level, too, the role of glutathione distinguishes itself from that of the other better known redox systems in affording protection against the tissue and cell damage detected during ageing, in Parkinson's disease, or in Alzheimer's disease. At the cerebral level,

in fact, glutathione is capable of playing various roles, and particularly that of a possible neurotransmitter. A deficiency of glutathione may increase the levels of cytotoxic substances and trigger the apoptosis of distinct sets of neuronal cells.

During ageing an increase in oxidative processes is observed and a reduction in natural antioxidant substances, including most notably glutathione, with the result that glutathione deficiency may be regarded as one of the causes of ageing. The favourable role of glutathione can also be observed at the intestinal level where its presence affects the formation of hydroperoxides and lipid peroxides, performing an important function of intestinal detoxification and in preventing the associated liver and bowel diseases.

L-carnitine and its alkanoyl derivatives are well known for the important role they may play at the metabolic level, particularly with regard to the oxidation and utilisation of fatty acids through β -oxidation.

L-carnitine, in fact, whether ingested with the diet or synthesised by the body, is concentrated by the blood in the organs which are metabolically most active in the utilisation of fatty acids, such as the skeletal muscles and heart.

An L-carnitine deficiency may be the cause of myopathy, whereas the oral administration of L-carnitine improves the clinical state associated with such diseases. L-carnitine also performs an important function in the mitochondrial oxidation of glucose in terms of energy production, with the result that adequate levels of L-carnitine are necessary for normal energy metabolism at the cardiac and muscular levels.

Its administration improves resistance to stress in subjects suffering from coronary insufficiency, as well as enhancing coronary flow, producing an improvement in the clinical effects of cardiac

decompensation.

Other biological properties of L-carnitine and its alkanoyl derivatives, particularly of propionyl L-carnitine, are its ability to stabilise the cell membranes and protect them
5 against the lesions induced by oxidative processes.

It has now surprisingly been found that a combination composition comprising as active ingredients:

- (a) propionyl L-carnitine or one of its pharmacologically acceptable salts;
- 10 (b) glutathione or a glutathione-containing yeast;
- (c) a glutathione-free yeast if the component (b) consists of glutathione;

is extremely effective in the prevention and/or treatment of abnormalities of the metabolically most active organs such as the liver, kidneys, cardiovascular system and brain, both as a result of the potent synergistic effect exerted by its components and as a
15 result of their increased tissue uptake, particularly of glutathione. Such a composition is particularly useful for the prevention or treatment of liver disease, kidney disease and cardiovascular or cerebral damage due to toxic substances.

It has also been found that, advantageously, component (a) may further comprise another
20 "carnitine", selected from the group comprising acetyl L-carnitine, valeryl L-carnitine and isovaleryl L-carnitine, or their pharmacologically acceptable salts or mixture thereof.

When component (a) of the composition consists of a mixture of carnitines, a mixture of L-carnitine, acetyl L-carnitine and propionyl L-carnitine or the pharmacologically
25 acceptable salts thereof, is preferred.

When component (b) consists of glutathione, component (c) will then consist of a glutathione-free yeast, selected from the group comprising *Saccharomyces cerevisiae* and *Saccharomyces fragilis*. Other examples of such yeasts are well known to experts in the
30 field.

When component (b) consists of a glutathione-containing yeast, the yeast should preferably contain from 7 to 10% of glutathione by weight. A non-limiting example of a suitable glutathione-containing yeast is the YH – Torula Yeast extract (*Candida utilis*) produced by Kohjin, Japan.

5

The (a):(b):(c) weight-to-weight ratio ranges from 100:1:100 to 1:10:10 and preferably from 10:1:10 to 1:1:1.

It has also been proved that both the synergistic effect and the tissue uptake are further increased when the composition also contains:

10

(d) at least one of the precursors of the biosynthesis of glutathione, selected from the group consisting of glutamic acid, glycine, cysteine and magnesium.

The optimal result is obtained when all the aforementioned precursors are present in the composition.

15

The preferred (a):(d) ratio is from 1:1 to 1:0.5.

The components constituting the combination according to the invention present an unexpected and surprising synergistic effect in protecting the body against toxic damages of exogenous origin, such as damage caused by environmental pollutants or by other damaging agents. In particular, the new composition may be usefully employed in situations of parenchymal distress of organs, such as, for instance, the liver, which as a result of their metabolic and detoxifying action are more exposed to lesions induced by external toxic agents.

20

25

The efficacy of the new composition stems both from the above-mentioned synergistic effect and from the increased active tissue concentrations of its components, particularly glutathione, as a result of their enhanced uptake.

30

The composition according to the invention can be used both as a food supplement or

5 dietary supplement with a prevalently preventive action and as a drug for the treatment of frank disease conditions. The metabolic effects exerted both by carnitines or glutathione or the glutathione-containing yeast and by the amino acids present in the composition are well known, and a deficiency of such compounds in the body may cause diseases even of a serious nature. It was not, however, predictable that their combination could powerfully enhance the effects and favour processes of uptake, thus increasing their tissue concentrations. In particular, various forms of liver and brain distress and intoxication due to heavy metals, chemotherapy agents or other drugs may benefit from the use of this composition.

10

The surprising synergistic effect produced by the combination of "carnitines" and glutathione in the presence of yeast and glutathione amino acid precursors and their enhanced uptake have been demonstrated in various pharmacological tests (some of which are described here below) selected because of their ability to provide highly predictive indications regarding the practical use of this composition both in the preventive/nutritional field and in the strictly therapeutic field.

15 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

20 The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

25

Toxicology tests

30 Prior to the various pharmacological tests the toxicity and tolerability limits of the new composition were tested in animals.

These toxicity tests were conducted both in rats and in mice, administering the various different products in combination in a single high-dose administration or administering them to the same animals continuously for at least sixty days. It was thus observed that one can administer an oral combination of up to 1 g/kg of propionyl L-carnitine and acetyl
5 L-carnitine together with 500 mg/kg of glutathione or 2 g/kg of yeast containing 10% glutathione and also the same products together with glutamic acid (100 mg/kg), glycine (100 mg/kg), cysteine (100 mg/kg) and magnesium (10 mg/kg) without the appearance of any sign of intolerance or toxicity. Also well tolerated is the prolonged administration for
10 sixty days of 0.5 g/kg of propionyl L-carnitine or acetyl L-carnitine together with 100 mg/kg of glutathione or with 1 g/kg of yeast extract containing 10% glutathione also together with glutamic acid (50 mg/kg), glycine (50 mg/kg) and magnesium (5 mg/kg).

Following these tests, examination of blood samples revealed no abnormalities of any kind in the animals treated. At autopsy, too, the histological tests performed on the main organs
15 detected no changes of a pathological nature as compared to control animals.

Pharmacological tests

To assess the antitoxic liver-protective effects of the new composition various tests were
20 selected from those which were not only better suited for revealing the pharmacological effects, but which were also reliably predictive for the purposes of its practical applications both as a nutritional and a pharmaceutical composition in the field of the prevention and treatment of liver diseases of toxic origin.

Acetaminophen (paracetamol) induced toxicity tests

Various groups of male mice received oral administrations of 600 mg/kg acetaminophen, which is a dose sufficient to cause death within 24 hours in 50% of the animals thus treated.

At the same time as the acetaminophen administration, one group of animals (group G) were administered glutathione (G) and a second (group YG) were administered yeast containing 10% glutathione (YG); a third group (group PC) were administered propionyl L-carnitine (PC); a fourth group (group AA) were administered a combination of glutamic acid, cysteine, glycine and magnesium (AA); a fifth group (group CC) were administered a first combination according to the invention, called the "complete combination" (CC), consisting of PC + G + AA, while a sixth group (group CYC) were administered a second combination according to the invention, called the "complete yeast combination" (CYC), consisting of PC + YG + AA.

The mortality 24 hours after treatment was observed in all the groups treated. The results of the test are given in Table 1.

The results of these tests indicate that, whereas partial protection against the mortality induced by acetaminophen is achieved with glutathione, no such protection is observed after propionyl L-carnitine or with the amino-acid combination. Glutathione-containing yeast shows a greater degree of protective activity than that afforded by glutathione alone. When the complete yeast combination, CYC, is administered, the protection appears to be total, thus demonstrating an evident synergism between glutathione, propionyl L-carnitine and the other components of the combination.

These synergistic effects appear even more marked when the mice are administered a 900 mg/kg acetaminophen dose, which causes the deaths of 100% of the animals. In this case, only administration of the complete yeast combination, CYC, protects more than 50% of the

animals treated against death (see Table 2).

The protection against acetaminophen at the dose of 900 mg/kg afforded by the new composition was even more marked when the animals were treated for 7 consecutive days prior to acetaminophen administration with the various components of the combination (see Table 3).

This result is probably related to the increased concentration of glutathione and the other components due to the greater tissue uptake related to the presence of yeast as well as to the increased synthesis of glutathione itself due to the greater presence of its precursors.

Table 1

Protection against acetaminophen-induced mortality (600 mg/kg/%).

Treatment/animal groups	mg/kg	Mortality
C	---	6/10
PC	100	6/10
G	50	4/10
YG	500	3/10
AA	130	5/10
CC	280	2/10
CYC	780	0/10

C = Controls
 PC = Propionyl L-carnitine
 G = Glutathione
 YG = Yeast containing 10% glutathione
 AA = Combination of amino acids and magnesium (glutamic acid 30 mg, cysteine 25 mg, glycine 50 mg + magnesium 5 mg)
 CC = Complete combination = (PC + G + AA)
 CYC = Complete yeast combination = (PC + YG + AA)

Table 2Protection against acetaminophen-induced mortality (900 mg/kg/%).

Treatment/animal groups	mg/kg	Mortality
C	---	10/10
PC	100	10/10
G	50	7/10
YG	500	6/10
AA	130	9/10
CC	280	5/10
CYC	780	3/10

Table 3Protection against acetaminophen-induced mortality (900 mg/kg/%) after prolonged prior administration of the composition or its components for 7 consecutive days.

Treatment	mg/kg	Mortality
C	---	10/10
PC	100	9/10
G	50	5/10
YG	500	3/10
AA	130	9/10
CC	280	1/10
CYC	780	0/10

Carbon tetrachloride (CCl₄) intoxication tests on isolated rat liver cells

In addition to intoxication with acetaminophen, the protective and synergistic activity exerted by the various components of the composition according to the invention are also detected at the hepatic level in relation to CCl₄ intoxication. The cells used in these tests were isolated rat liver cells after perfusion with collagenase according to the method described by Seglen (Seglen F.O., Method Cell. Biol. Chem. 264:4747, 1989). Approximately 4-6 x 10⁸ viable liver cells were collected, calculated by exclusion of non-viable cells by means of trypan blue.

The cells thus isolated were suspended in 25 cm² plastic receptacles in the presence of antibiotics and 10% inactivated fetal calf serum. To the cell suspension thus obtained was added CCl₄ (10 mmol.L⁻¹), glutathione (GSH 20 mg.L⁻¹), propionyl L-carnitine (100 mg.L⁻¹) or glutathione combined with propionyl L-carnitine. After a 4-h incubation the percentage of dead cells was estimated by release of lactate dehydrogenase, as described by Casini et al. (Casini et al., J. Biol. Chem., 257:6721, 1982). The examination of the protective effect against CCl₄ intoxication exerted by glutathione, propionyl L-carnitine and their use in combination was determined by assay of culture supernatant for both alanine aminotransferase (Ala AT) and aspartate aminotransferase (Asp AT) (Auto-biochemistry Assay System Beckman 700-Encore 2).

The cytological examination of the liver cells was done under both the light and electron microscope after fixation in 3% formalin and paraffin for light microscopy and 3% glutaraldehyde and 1% osmium tetroxide for electron microscopy.

The results of this analysis (see Tables 4, 5 and 6) demonstrate that both glutathione and propionyl L-carnitine are capable of reducing the toxic effects of carbon tetrachloride.

Surprisingly, higher effect was obtained from the combination of glutathione together with PLC.

In this case, the percentage of dead cells was reduced practically to zero. The increase in enzyme concentrations indicative of metabolic functional damage (Ala AT - Asp AT) was also unexpectedly substantially reduced by the combination of glutathione and propionyl L-carnitine. Confirmation of the intense synergistic effect of glutathione and propionyl L-carnitine was also provided by the histological examinations which, at light microscopy, revealed the virtually complete disappearance of necrotic cells and, at electron microscopy, showed preservation of the intracellular structures and, in

particular, of the mitochondrial structures and the number of ribosomes.

Table 4

Protection in CCl₄-intoxicated liver cell cultures

Treatment	% dead cells
CCl ₄	85 ± 4
Glutathione	55 ± 5
Propionyl L-carnitine	70 ± 7
Glutathione + Propionyl L-carnitine	5 ± 3

Table 5

Protection in CCl₄-intoxicated liver cell cultures. Concentrations of alanine aminotransferase (Ala AT nmol.min⁻¹ L⁻¹) and of aspartate aminotransferase (Asp AT nmol.min⁻¹.L⁻¹) in supernatant after 4 hours

Treatment	Ala AT	Asp AT
CCl ₄	26.5 ± 3.1	9.08 ± 0.7
Glutathione	19.7 ± 2.5	7.5 ± 5.4
Propionyl L-carnitine	22.4 ± 2.8	8.9 ± 0.9
Glutathione + Propionyl L-carnitine	7.7 ± 1.9	3.4 ± 2.1

Carbon tetrachloride-induced liver intoxication tests

Another indicator of CCl₄ toxicity in the liver is provided by the increased hepatic concentration of triglycerides. In this test, too, the protective activity of glutathione, propionyl L-carnitine, amino acids and yeast, both alone and in combination in the composition according to the invention, was demonstrated.

The CCl₄ intoxication was induced by giving fasting rats an intraperitoneal injection of 1 ml.kg⁻¹ of a suspension of 20% CCl₄ in olive oil. Prior to CCl₄ intoxication the rats were treated for three consecutive days with glutathione (G = 50 mg/kg), or with propionyl L-carnitine (PC = 100 mg/kg), or with yeast containing 10% glutathione

(YG = 500 mg/kg), or with a combination of amino acids (AA = glutamic acid 50 mg, cysteine 25 mg, glycine 50 mg, magnesium 5 mg). or with the complete combination CC (CC = PC + G + AA), or with the complete yeast combination CYC (CYC = PC + YG + AA). After administration of CCl₄, the livers were excised from the decapitated animals and were used to measure the triglyceride concentration according to the method described by Donabedian (Donabedian R.K., Clin. Chem., 20:632, 1974). The results of these tests also revealed a substantial synergism between glutathione and propionyl L-carnitine in protecting the liver against CCl₄ intoxication.

Even more marked was the protective effect of the combination of propionyl L-carnitine with yeast and the amino acid complex. In this case, in fact, liver infiltration by triglycerides was practically non-existent, thus demonstrating the powerful synergism achieved by the composition according to the invention (see Table 6).

Table 6

Tests on increase in liver triglycerides induced by CCl₄

CCl ₄ (ml.kg ⁻¹)	Treatments	Triglycerides (mg.g ⁻¹)
0	---	5.9 ± 0.4
1	---	26.9 ± 1.1
1	PC	20.2 ± 1.9
1	G	18.7 ± 2.1
1	YG	16.5 ± 1.2
1	AA	20.4 ± 2.1
1	CC	12.5 ± 1.4
1	CYC	9.9 ± 0.6

Protection against experimental hypertriglyceridaemia in the rat

The method used for this test was that described by Carlson (Carlson L.A.V., J. Atheroscl. Res., 8:667, 1968) and modified as described in Atherosclerosis, 16:349, 1972. According to this test oral administration of 3 g/kg of fructose in the rat induces a substantial increase in both liver and serum triglycerides five hours after administration.

The aim of this test was to assess whether the administration of the components of the composition according to the invention, when used alone or in combination, were capable of leading to a reduction in this triglyceride abnormality which is regarded as underlying severe liver dysfunctions as well as atherosclerosis.

To this end, various groups of rats were treated with glutathione (G = 50 mg/kg), with propionyl L-carnitine (PC = 50 mg/kg), or with yeast containing 10% glutathione (YG = 500 mg/kg), or with an amino acid mixture (AA = glutamic acid 50 mg/kg, cysteine 25 mg/kg, glycine 100 mg/kg + magnesium 5 mg/kg), or with a combination of these various components (at the same doses) without yeast (CC) or with yeast (CYC). The treatment was given orally on the three days preceding fructose administration and for three hours after its administration. Five hours after fructose administration all animals were sacrificed and blood samples were used to assay triglycerides according to the method described by Donabedian (Donabedian R.K., Clin. Chem., 20:632, 1974). The results of these tests indicate that both glutathione and propionyl L-carnitine have small efficacy on serum triglyceride levels induced by the administration of fructose, but that a marked effect is obtained when these compounds are given in combination, particularly in the presence of yeast. A substantial reduction in triglycerides was, in fact, observed in the blood of rats who had been administered the complete combination together with yeast and amino acids, thus demonstrating the powerful synergism between the various components of the combination (see Table 7).

Table 7Tests on hypertriglyceridaemia (mg/100 ml) induced in the rat

Controls	190 ± 6.7
G	180 ± 5.9
YG	175 ± 6.9
PC	185 ± 7.1
YG + PC	155 ± 8.1
AA	185 ± 6.5
CC	140 ± 4.3
CYC	133 ± 6.3

Experimental atherosclerosis tests

The method used in this test was that described by Malinow (Malinow M.R., Atherosclerosis, 48:105, 1983). According to this test, the administration for six weeks consecutively to male Wistar rats of an atherogenic diet consisting of 10% cotton oil, 24% casein, 1% cholesterol, 60% sugar, and vit. D₂ 200 mUST/g diet induces pronounced vascular atherosclerotic lesions. These are determined at the level of the aorta by measuring the thickness of the abdominal aorta using a morphometric method and the intensity of the staining induced by Sudan IV and by evaluating their severity with a scoring system from 1 to 5.

The morphometric assessments and the intensity of the Sudan IV staining again revealed, in these tests, too, a substantial synergism between glutathione (25 mg/kg) and propionyl L-carnitine (100 mg/kg), but the protective effect was even more marked when the complete yeast combination was used. In the group of rats treated with CYC the occurrence of vascular atherosclerotic lesions appeared, in fact, to be completely inhibited, demonstrating in this case, too, the synergistic activity of the various components of the combination according to the invention.

Activity against glycerol-induced nephropathy

The method used in this test was that described by Young (Young J.H.K., Meth. Find. Exp. Clin. Pharmacol., 13:23, 1991). According to this test, a glycerol injection induces kidney failure and nephropathy in the rat. This method was used to assess the protective effects of the combination according to the invention on the kidney. Male Sprague-Dawley rats were used, which, after being deprived of drinking water for 24 hours, were injected with 10 cc/kg of a 50% w/v solution of glycerol and water. After the injection, the animals thus treated were allowed to drink. After 24 hours, blood samples were taken from the animals and, after centrifuging, the plasma creatinine concentration was assayed (according to the method described by Taussky H.H., Clin. Chem. Acta, 1:210, 1956) and urea by means of reaction with diacetylmonoxime (Henry R.Y., Cannon D.C. Eds., Clinical Chemistry, 2 Ed. Harper & Rowe, London 1974). Propionyl L-carnitine (100 mg/kg), glutathione (50 mg/kg) or yeast containing glutathione (500 mg/kg), amino acids (25 mg/kg each), yeast (500 mg/kg) and a combination of these at the same doses were administered daily on the three days preceding the test. The results of this test (see Table 8) indicate that both propionyl L-carnitine and glutathione have a fairly good protective effect against glycerol-induced kidney lesions, but greater efficacy is obtained by their combined use, particularly in the presence of yeast. With the presence of amino acids, in addition to yeast, the protection afforded is practically total, thus demonstrating the effective potentiation of activity obtained with the combination and not only the synergism which exists between propionyl L-carnitine and glutathione but also the favourable action exerted by yeast and amino acids on this combination.

Table 8Protective activity against glycerol-induced kidney failure in the rat

Treatment	Creatinine (mg/ml)	Urea (mg/100 ml)
Controls	56.8 ± 7.7	22.2 ± 1.9
Glycerol	360.4 ± 55.2	116.7 ± 19.4
Propionyl L-carnitine	280.5 ± 22.5	88.5 ± 11.5
Glutathione	240.8 ± 20.9	79.9 ± 9.9
Propionyl L-carnitine + Glutathione	185.5 ± 19.2	60.2 ± 6.5
Propionyl L-carnitine + Yeast (10% glutathione)	160.8 ± 16.8	52.5 ± 6.1
Amino acids	320.4 ± 50.6	105.5 ± 14.9
Propionyl L-carnitine + Glutathione + Amino acids + Yeast	95.4 ± 9.2	38.4 ± 4.1

Effects on glutathione (GSH) concentration in elderly rats

Since the metabolic and enzymatic activity of glutathione is known to be reduced in elderly rats and this reduction is regarded as one of the causes of ageing, the effect of the administration of the new composition or its individual components on glutathione concentrations in the plasma and liver of young and elderly rats was evaluated.

For this test two different groups of rats were used: young rats (2-3 months) and elderly rats (8-10 months). The glutathione (GSH) concentration was calculated in both groups according to the technique described by Moron (Moron M.S., Biochem. Biophys. Acta, 582:67, 1979) both before the start of the test and after 15 days' daily administration of propionyl L-carnitine (100 mg/kg), glutathione (50 mg/kg), propionyl L-carnitine with glutathione or with yeast containing 10% glutathione (500 mg/kg), amino acids (500 mg/kg) or the combination according to the invention.

After 15 days of treatment, assay of the glutathione concentrations present in both the liver (see Table 9) and plasma (see Table 10) showed the reciprocal potentiation of propionyl L-carnitine and glutathione in restoring normal glutathione concentrations in elderly

rats. The synergism, however, was even more marked in the presence of yeast and amino acids when mixed in the composition according to the invention.

Table 9

Effects on glutathione concentration (GSH ng/mg protein) in young and elderly rat livers

Treatment	Young rats		Elderly rats	
	time		time	
	0	15 days	0	15 days
Controls	11.55 ± 0.88	12.75 ± 0.91	8.70 ± 0.72	8.10 ± 0.63
Propionyl L-carnitine	11.25 ± 0.41	12.90 ± 0.71	7.9 ± 0.51	9.3 ± 0.46
Glutathione	12.1 ± 0.36	12.85 ± 0.66	8.82 ± 0.69	9.90 ± 0.76
Propionyl L-carnitine + Glutathione	12.70 ± 0.64	13.05 ± 0.55	8.10 ± 0.71	10.50 ± 0.40
Propionyl L-carnitine + Yeast (10% glutathione)	11.73 ± 0.49	13.75 ± 0.62	8.75 ± 0.41	10.80 ± 0.71
Amino acids	11.25 ± 0.68	12.68 ± 0.41	8.90 ± 0.57	9.15 ± 0.68
Propionyl L-carnitine + Glutathione + Amino Acids + Yeast	11.35 ± 0.77	12.45 ± 0.59	8.25 ± 0.61	11.95 ± 0.85

Table 10

Effects on glutathione (GSH) concentration (GSH mg/dl) in young and elderly rat plasma

Treatment	Young rats		Elderly rats	
	time		time	
	0	15 days	0	15 days
Controls	2.12 ± 0.59	2.25 ± 0.39	1.39 ± 0.49	1.35 ± 0.55
Propionyl L-carnitine	2.22 ± 0.29	2.39 ± 0.50	1.40 ± 0.22	1.75 ± 0.20
Glutathione	2.09 ± 0.31	2.35 ± 0.35	1.26 ± 0.31	1.80 ± 0.41
Propionyl L-carnitine + Glutathione	2.14 ± 0.21	2.40 ± 0.40	1.22 ± 0.21	1.95 ± 0.35
Propionyl L-carnitine + Yeast (10% glutathione)	2.20 ± 0.19	2.48 ± 0.33	1.35 ± 0.33	2.05 ± 0.29
Amino acids	2.27 ± 0.27	2.42 ± 0.29	1.33 ± 0.21	1.40 ± 0.34
Propionyl L-carnitine + Glutathione + Amino Acids + Yeast	2.10 ± 0.16	2.36 ± 0.26	1.25 ± 0.16	2.25 ± 0.39

Effects on glutathione uptake and concentration in blood of glutathione-depleted animals

The aim of these tests was to demonstrate that the composition according to the invention favours the uptake of glutathione as a result of the presence of yeast.

To this end, the glutathione content in the blood of a group of Sprague-Dawley male rats was reduced by means of the administration of diethylmaleate (DEM) a depletor of glutathione, according to the technique described by Plummer (Plummer J., Chemical depletion of glutathione "in vivo", Methods in Enzymology, 77:50, 1981). DEM was administered intraperitoneally to fasting rats at the dose of 1 cc/kg. Half an hour after injection of diethylmaleate, glutathione alone (50 mg/kg), or yeast containing 10% glutathione (500 mg/kg), or 50 mg/kg of glutathione together with 500 mg of yeast not containing glutathione were administered orally. Another group of rats received glutathione amino acid precursors (glutamic acid 50 mg/kg, glycine 50 mg/kg, cysteine 50 mg/kg, magnesium 10 mg/kg) or the complete combination according to the invention at the same doses as described here above.

After four hours blood samples were taken from the animals thus treated and the plasma glutathione concentration was measured. The results of these tests (see Table 11) indicate that glutathione uptake is substantially increased by the presence of yeast, whether the yeast contains glutathione or is simply used in combination with glutathione.

The presence of yeast caused a significant increase in glutathione plasma concentrations in rats in which these concentrations had been reduced by injection of DEM.

This effect was even more marked when the glutathione-depleted animals were administered the complete combination according to the invention.

Table 11

Effects on glutathione (GSH) concentration in plasma (GSH mg/dl) in glutathione-depleted rats by injecting diethylmaleate (DEM). Values measured 4 h after injection.

	Glutathione (GSH mg/dl)
Controls	2.70 ± 0.41
DEM	0.61 ± 0.74
Propionyl L-carnitine	0.70 ± 0.54
Glutathione	0.95 ± 0.88
Yeast (10% glutathione)	1.65 ± 0.90
Glutathione + Yeast	1.85 ± 0.80
Amino acids	0.85 ± 0.70
Glutathione + Amino acids	1.10 ± 0.66
Propionyl L-carnitine + Glutathione + Amino acids + Yeast	2.15 ± 1.1

Some non-limiting examples of composition according to the invention are reported hereinbelow.

1)	Carnitine mixture	200 mg
	(L-carnitine 50 mg, acetyl L-carnitine 50 mg, propionyl L-carnitine 50 mg, isovaleryl L-carnitine 50 mg)	
	Yeast (titled 7-10% glutathione)	200 mg
	Glutamic acid	50 mg
	L-cysteine	50 mg
	Glycine	50 mg
	Magnesium citrate	10 mg
2)	Carnitine mixture	200 mg
	(L-carnitine 50 mg, acetyl L-carnitine 50 mg, propionyl L-carnitine 50 mg, isovaleryl L-carnitine 50 mg)	
	Glutathione (GHS)	50 mg
	Glutamic acid	50 mg
	L-cysteine	50 mg
	Glycine	50 mg
	Magnesium citrate	10 mg
	Yeast (<i>Saccharomyces cerevisias</i>)	200 mg

3)	Propionyl L-carnitine	200 mg
	Yeast (titled 7-10% glutathione)	200 mg
	Glutamic acid	50 mg
	L-cysteine	50 mg
	Glycine	50 mg
	Magnesium citrate	10 mg
4)	Propionyl L-carnitine	200 mg
	Glutathione (GHS)	50 mg
	Glutamic acid	50 mg
	L-cysteine	50 mg
	Glycine	50 mg
	Magnesium citrate	10 mg
	Yeast (<i>Saccharomyces cerevisias</i>)	200 mg
5)	Propionyl L-carnitine	200 mg
	Glutathione	100 mg
	Glutamic acid	50 mg
	L-cysteine	50 mg
	Glycine	50 mg
	Magnesium citrate	10 mg
	Yeast (<i>Saccharomyces cerevisias</i>)	200 mg
6)	Propionyl L-carnitine	200 mg
	Yeast (titled 7-10% glutathione)	300 mg
	Glutamic acid	50 mg
	L-cysteine	50 mg
	Glycine	50 mg
	Magnesium citrate	10 mg
7)	Propionyl L-carnitine	200 mg
	Glutathione (GSH)	100 mg
	Glutamic acid	50 mg
	L-cysteine	50 mg
	Glycine	50 mg
	Magnesium citrate	10 mg
	β -carotene	5 mg
	α -carotene	5 mg
	Coenzyme Q ₁₀	10 mg
	Selenium methionine	20 μ g
	Yeast (<i>Saccharomyces cerevisias</i>)	200 mg

8)	Propionyl L-carnitine	200 mg
	Yeast (titled 7-10% glutathione)	300 mg
	Glutamic acid	50 mg
	L-cysteine	50 mg
	Glycine	50 mg
	Magnesium citrate	10 mg
	β -carotene	5 mg
	α -carotene	5 mg
	Coenzyme Q ₁₀	10 mg
	Vit. PP	25 mg
	Vit. B ₆	25 mg
	Vit. B ₁₂	250 μ g
	Selenium methionine	20 μ g

What is meant by pharmacologically acceptable salt of L-carnitine or alkanoyl L-carnitine is any salt of these active ingredients with an acid that does not give rise to unwanted toxic or side effects. These acids are well known to pharmacy experts.

Non-limiting examples of suitable salts are the following: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate; acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; orotate; oxalate, acid oxalate; sulphate, acid sulphate, trichloroacetate, trifluoroacetate and methanesulphonate.

A list of FDA-approved pharmacologically acceptable salts is given in Int. J. of Pharm. 33, (1986), 201-217; this latter publication is incorporated herein by reference.

The composition according to the invention may also comprise vitamins, coenzymes, mineral substances and antioxidants.

Appropriate excipients to be used to prepare the compositions having regards to the specific route of administration, will be apparent to the pharmacy and food industry experts.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A combination composition which comprises:
 - (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof; and
 - 5 (b) glutathione or a glutathione-containing yeast;
 - (c) a glutathione-free yeast if the component (b) consists of glutathione.

2. The composition of claim 1, wherein the ingredient (a) further comprises a
"carnitine" selected from the group comprising L-carnitine, acetyl L-carnitine, valeryl L-
10 carnitine, isovaleryl L-carnitine or their pharmacologically acceptable salts or mixtures
thereof.

3. The composition of claim 2, wherein the ingredient (a) comprises a mixture of L-
carnitine, acetyl L-carnitine and propionyl L-carnitine or their pharmacologically
15 acceptable salts.

4. The composition of any one of claims 1-3, wherein the glutathione-containing yeast
contains from 7 to 10% by weight of glutathione.

- 20 5. The composition of any one of claims 1-4, wherein the weight ratio (a):(b):(c) is
from 100:1:100 to 1:10:10.

6. The composition of any one of claims 1-4, wherein the weight ratio (a):(b):(c) is
from 10:1:10 to 1:1:1.

- 25 7. The composition of any one of claims 1-5, which further comprises:
 - (d) at least one of the precursors of the biosynthesis of glutathione, selected from the
group comprising glutamic acid, cysteine and magnesium.

- 30 8. The composition of claim 7, wherein the weight ratio (a):(d) is from 1:1 to 1:0.5.

9. The composition of claim 1 or claim 7, which comprises:
- (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof;
 - (b) glutathione;
 - (c) a glutathione-free yeast, selected from the group comprising *Saccharomyces cerevisiae* and *Saccharomyces fragilis*;
 - (d) glutamic acid, glycine, cysteine and magnesium.
10. The composition of any one of claims 1 and 4-7, which comprises:
- (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof;
 - (b) a yeast containing 7-10% by weight of glutathione;
 - (c) glutamic acid, glycine, cysteine and magnesium.
11. The composition of any one of claims 1 and 3-7, which comprises:
- (a) a mixture of L-carnitine, acetyl L-carnitine, propionyl L-carnitine or their pharmacologically acceptable salts;
 - (b) glutathione;
 - (c) a glutathione-free yeast, selected from the group comprising *Saccharomyces cerevisiae* and *Saccharomyces fragilis*;
 - (d) glutamic acid, glycine, cysteine and magnesium.
12. The composition of any one of claims 1 and 3-6, which comprises:
- (a) a mixture of L-carnitine, acetyl L-carnitine, propionyl L-carnitine or their pharmacologically acceptable salts thereof;
 - (b) a yeast containing 7-10% by weight of glutathione;
 - (c) glutamic acid, glycine, cysteine and magnesium.
13. The composition of any one of the preceding claims wherein the pharmacologically acceptable salt of L-carnitine or alkanoyl L-carnitine is selected from the group comprising: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; orotate; acid oxalate; sulphate, acid sulphate;

trichloroacetate; trifluoroacetate and methane sulphonate.


14. The composition of any one of the preceding claims, which further comprises vitamins, coenzymes, mineral substances and antioxidants.

5

15. The composition of any one of the preceding claims, orally administrable, in the form of a dietary supplement.


16. The composition of any one of the preceding claims, orally, parenterally, rectally or
10 transdermally administrable, in the form of a medicament.

17. The dietary supplement of claim 15, for the prevention of hepatosis, nephropathies and cardiovascular or cerebral damage provoked by external toxic substances.




15 18. The medicament of claim 16, for the therapeutic treatment of hepatosis, nephropathies and cardiovascular or cerebral damages provoked by external toxic substances.

19. The dietary supplement of claim 17, in the form of tablets, lozanges, pills, capsules,
20 granulates or syrups.



20. The medicament of claim 18, in the form of tablets, lozanges, pills, capsules, granulates, syrups, suppositories, vials or drops.



25 21. Use of the composition of any one of claims 1 to 14 for preparing a dietary supplement or a medicament useful for the prevention or treatments of lesions induced by external toxic substances.

22. Use according to claim 20 wherein the combination further comprises:

30 (d) at least one of the precursors of the biosynthesis of glutathione, selected from the group comprising glutamic acid, glycine, cysteine and magnesium.

23. The use of claims 20 or 21 wherein the dietary supplement or medicament is useful to prevent/treat hepatitis, nephropathies and cardiovascular or cerebral damages provoked by external toxic substances.

5 24. A method of treating or preventing lesions induced by external toxic substances comprising administering to a subject a composition according to any one of claims 1 to 14.

25. A method according to claim 24 wherein the combination further comprises:

10 (d) at least one of the precursors of the biosynthesis of glutathione, selected from the group comprising glutamic acid, glycine, cysteine and magnesium.

26. A method of claim 24 or 25 wherein the lesions induced by external toxic substances result in hepatitis, nephropathies and cardiovascular or cerebral damages.

15

27. A combination composition according to claim 1, substantially as hereinbefore described.

28. Use according to claim 21, substantially as hereinbefore described.

20

29. A method according to claim 24, substantially as hereinbefore described.

DATED this 5th day of April, 2004

25

Sigma-Tau HealthScience S.p.A.

By DAVIES COLLISON CAVE
Patent Attorneys for the Applicants